ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing of Different Biomarkers From Vena Rectalis Superior and Vena Cubiti in Patients Undergoing Low Anterior Resection for Rectum Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01706809
Recruitment Status : Unknown
Verified February 2014 by Mark Ellebaek Pedersen, Odense University Hospital.
Recruitment status was:  Recruiting
First Posted : October 15, 2012
Last Update Posted : February 5, 2014
Sponsor:
Information provided by (Responsible Party):
Mark Ellebaek Pedersen, Odense University Hospital

Brief Summary:
The primary aim of the present study is to investigate different biomarkers like VEGF, EVGF and others ability to predict time to recidive and progressions free survival.

Condition or disease Intervention/treatment
Rectal Cancer Other: blood sampels from vena rectalis superior and vena cubiti

Detailed Description:

Patients undergoing LAR for rectum cancer is subjected. Preoperative blood samples from vena rectalis superior and vena cubiti is collected, as well as biopsies from tumor. Preoperative and after 3 month peripheral blood samples is collected.

A total of 50 patients will be included in this study.

The study is approved by the local scientific ethical committee No. S-20100006


Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Case Control
Time Perspective: Prospective
Study Start Date : September 2011
Estimated Primary Completion Date : September 2015
Estimated Study Completion Date : December 2015

Group/Cohort Intervention/treatment
Biomarkeres Other: blood sampels from vena rectalis superior and vena cubiti



Primary Outcome Measures :
  1. The primary aim of the present study is to investigate different biomarkers like VEGF, EVGF and others ability to predict time to recidive and progressions free survival. [ Time Frame: after the study is complete ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients undergoing open LAR for rectum cancer is subjected.
Criteria

Inclusion Criteria:

  • Histological verified cancer
  • The cancer must be located in rectum maximum of 15 cm.
  • Age above 18

Exclusion Criteria:

  • Disseminated cancer
  • Perioperative radio-chemotherapy
  • Laparoscopy surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01706809


Locations
Denmark
Vejle hospital Recruiting
Vejle, Denmark, 5000
Contact: Hans Rahr, MD    7940 5600 ext 0045    hans.rahr@slb.regionsyddanmark.dk   
Sponsors and Collaborators
Odense University Hospital

Responsible Party: Mark Ellebaek Pedersen, Medical doctor, Odense University Hospital
ClinicalTrials.gov Identifier: NCT01706809     History of Changes
Other Study ID Numbers: S-20100006
S-20100006
First Posted: October 15, 2012    Key Record Dates
Last Update Posted: February 5, 2014
Last Verified: February 2014